Yan Kong

7PUBLICATIONS
42CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunologyImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

|Apr 15, 2026
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

|Apr 24, 2025
MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma.

Fenghao Zhang, Haizhen Du, Kaiping Liu

|Sep 05, 2023
A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.

Jing Shi, Tao Jiao, Qian Guo

|Oct 25, 2022
Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma.

Xu Xiao, Qian Guo, Chuanliang Cui

|Feb 05, 2021
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma.

Chuanliang Cui, Canqiang Xu, Wenxian Yang

Pageof 2

Frequent Collaborators

3 joint publications

Xinan Sheng

3 joint publications

Jun Guo

2 joint publications

Wenxian Yang

2 joint publications

Rongshan Yu